MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1096-1102

  Luo, Qifeng ^a   Wei, Chuankui ^a   Li, Xiaoyu ^a   Li, Jia ^b   Chen, Lei ^a   Huang, Yixiang ^a   Song, Hongming ^a   Li, Dengfeng ^a   Fang, Lin ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Breast cancer; microRNA; miR 195 5p

Indexed keywords

CYCLIN E; CYCLIN E1; LUCIFERASE; MICRORNA; MICRORNA 195 5P; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYCLIN E1 GENE; ENZYME ASSAY; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN E; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICRORNAS; ONCOGENE PROTEINS; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84896702200     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2971     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007. (Pubitemid 350232263)
3. De Santa F, Iosue I, Del Rio A and Fazi F: microRNA biogenesis pathway as a therapeutic target for human disease and cancer. Curr Pharm Des 19: 745-764, 2013.
4. Sung H, Jeon S, Lee KM, et al: Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival. BMC Cancer 12: 195, 2012.
5. Vasudevan S, Tong Y and Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931-1934, 2007.
6. Ryan BM, Robles AI and Harris CC: Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389-402, 2010.
7. Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007. (Pubitemid 350235025)
8. Mattiske S, Suetani RJ, Neilsen PM and Callen DF: The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev 21: 1236-1243, 2012.
9. Radisky DC: miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast Cancer Res 13: 110, 2011.
10. Li D, Zhao Y, Liu C, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 17: 1722-1730, 2011.
11. Sauer K and Lehner CF: The role of cyclin E in the regulation of entry into S phase. Prog Cell Cycle Res 1: 125-139, 1995.
12. Nakayama N, Nakayama K, Shamima Y, et al: Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116: 2621-2634, 2010.
13. Mao L, Ding J, Perdue A, et al: Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene 31: 3785-3795, 2012.
14. Keyomarsi K, Tucker SL, Buchholz TA, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med 347: 1566-1575, 2002. (Pubitemid 35315837)
15. Sgambato A, Camerini A, Collecchi P, et al: Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci 100: 1026-1033, 2009.
16. Han JY, Wang H, Xie YT, et al : Association of germline variation in CCNE1 and CDK2 with breast cancer risk, progression and survival among Chinese Han women. PLoS One 7: e49296, 2012.
17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
18. den Hollander P, Savage MI and Brown PH: Targeted therapy for breast cancer prevention. Front Oncol 3: 250, 2013.
19. Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72: 908-916, 2012.
20. Li B, Shi XB, Nori D, et al: Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 71: 567-574, 2011.
21. Tatarano S, Chiyomaru T, Kawakami K, et al: Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. Int J Oncol 40: 951-959, 2012.
22. Li LZ, Zhang CZ, Liu LL, et al: miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis: Nov 1, 2013 (Epub ahead of print).